Market Research Logo

Asia Pacific Hyperphosphatemia Drug Market Forecast 2019-2027

Asia Pacific Hyperphosphatemia Drug Market Forecast 2019-2027

KEY FINDINGS

The Asia-Pacific hyperphosphatemia drugs market was worth $xx million in 2018. The market is estimated to grow at a CAGR of 17.37% during the forecast period of 2019-2027 and generate $xx million by the end of 2027. Diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. The growing prevalence of such chronic diseases, increasing elderly population, unmet medical attention, and the rise in public awareness are the major drivers for the hyperphosphatemia drugs market in this region. The Asia-Pacific regions are expected to further propel the growth of the market in the coming years.

MARKET INSIGHTS

Increased cases of osteoporosis in the ageing population are observed in the Asia-Pacific regions, which are mostly going undertreated and underdiagnosed. This lapse is majorly responsible for the demand of the hyperphosphatemia drugs market in the Asian countries. The Indian hyperphosphatemia drugs market is growing with the highest CAGR of xx% during the forecast period. Growing elderly population in India is the key driving factor responsible for increasing the demand of the hyperphosphatemia drugs market in this region. The hyperphosphatemia drug market is segmented on the basis of the drug formulation. They include iron-based phosphate binders, calcium-based phosphate binders, magnesium-based phosphate binders, aluminium-based phosphate binders, and other phosphate binders. The Calcium-based phosphate binder’s formulation is expected to lead the hyperphosphatemia drugs market during the forecast years. The Aluminium-based phosphate binders generated a revenue of $xx million in 2018 and are widely being used for the treatment of hyperphosphatemia in dialysis patients. The magnesium-based phosphorus binders are another widely used phosphorus binders, which also are remarkably being engaged in curing the hyperphosphatemia conditions in all the dialysis patients.

COMPETITIVE INSIGHTS

The major players in the hyperphosphatemia drug market are Johnson And Johnson, Cipla, Dsm, Biotech Pharmacal, Sun Pharm Inc, Zeria Pharmaceutical, Ultragenyx, Bruno Farmaceutici Spa, Fermenta Biotech Ltd, Fresenius Medical Care Pfizer Inc, Roche Diagnostics Corporation, Keryx Biopharmaceuticals , R.H. Moore Drug Co, Vifor Pharma, Sanofi, and Amag Pharmaceuticals.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
2.5. Estimation Methodology
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Iron-based Hyperphosphatemia Drugs Is A Game Changer
4. Market Determinants
4.1. Market Scope & Definition
4.2. Drivers
4.2.1. Growing Prevalence Of Chronic Diseases
4.2.2. Unmet Medical Needs
4.2.3. Skewed Population Mix Towards Elderly People
4.2.4. Rise In Public Awareness
4.3. Restraints
4.3.1. Limitations Levied By The Food And Drug Administration (Fda)
4.3.2. Growing Side Effects Of The Hyperphosphatemia Drugs
4.4. Challenges
4.4.1. Non-adherence To Treatment Regimens
4.4.2. Side Effects Of Drugs
4.4.3. Limited Availability Of Drugs
4.4.4. Use Of Advanced Dialysis Techniques
4.5. Market By Dosage
4.5.1. Solid
4.5.1.1. Tablet
4.5.1.2. Powder
4.5.2. Liquid
4.5.2.1. Solution
5. Market By Formulation
5.1.1. Calcium-based Phosphate Binders
5.1.2. Aluminum-based Phosphate Binders
5.1.3. Magnesium-based Phosphate Binders
5.1.4. Iron-based Phosphate Binders
5.1.5. Other Phosphate Binders
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Bargaining Power Of Buyers
6.1.3. Bargaining Power Of Suppliers
6.1.4. Threat Of Substitute Product
6.1.5. Intensity Of Competitive Rivalry
6.2. Opportunity Matrix
6.3. Key Buying Criteria
6.3.1. Application
6.3.2. Pricing
6.3.3. Effectiveness
6.3.4. Availability
6.4. Strategic Recommendation & Strategic Conclusions
6.5. Market Trends
6.5.1. Patient Assistance Programs
6.5.2. Strategic Alliances
6.5.3. Increase In R&D
6.6. Phosphate Binders Usages Guidelines
7. Geographic Analysis
7.1. Asia Pacific
7.1.1. India
7.1.2. China
7.1.3. Japan
7.1.4. Australia
7.1.5. South Korea
7.1.6. Rest Of Apac
8. Competitive Landscape
8.1. Market Share Analysis
8.2. Company Profiles
8.2.1. Amag Pharmaceuticals
8.2.1.1. Overview
8.2.1.2. Product Portfolio
8.2.1.3. Scot Analysis
8.2.1.4. Strategic Initiatives
8.2.2. Biotech Pharmacal
8.2.2.1. Overview
8.2.2.2. Products Portfolio
8.2.2.3. Scot Analysis
8.2.2.4. Strategic Initiatives
8.2.3. Bruno Farmaceutici Spa
8.2.3.1. Overview
8.2.3.2. Product Portfolio
8.2.3.3. Scot Analysis
8.2.3.4. Strategic Initiatives
8.2.4. Cipla
8.2.4.1. Overview
8.2.4.2. Product Portfolio
8.2.4.3. Scot Analysis
8.2.4.4. Strategic Initiatives
8.2.5. Fermenta Biotech Ltd
8.2.5.1. Overview
8.2.5.2. Product Portfolio
8.2.5.3. Scot Analysis
8.2.5.4. Strategic Initiatives
8.2.6. Fresenius Medical Care
8.2.6.1. Overview
8.2.6.2. Product Portfolio
8.2.6.3. Scot Analysis
8.2.6.4. Strategic Initiatives
8.2.7. Johnson And Johnson
8.2.7.1. Company Overview
8.2.7.2. Product Portfolio
8.2.7.3. Scot Analysis
8.2.7.4. Strategic Initiatives
8.2.8. Keryx Biopharmaceuticals Inc
8.2.8.1. Overview
8.2.8.2. Scot Analysis
8.2.8.3. Strategic Initiatives
8.2.9. Pfizer Inc.
8.2.9.1. Overview
8.2.9.2. Product Portfolio
8.2.9.3. Scot Analysis
8.2.9.4. Strategic Initiatives
8.2.10. Roche Diagnostics Corporation
8.2.10.1. Overview
8.2.10.2. Product Portfolio
8.2.10.3. Scot Analysis
8.2.10.4. Strategic Initiatives
8.2.11. Royal Dsm N.V.
8.2.11.1. Overview
8.2.11.2. Product Portfolio
8.2.11.3. Scot Analysis
8.2.11.4. Strategic Initiatives
8.2.12. Sanofi
8.2.12.1. Overview
8.2.12.2. Product Portfolio
8.2.12.3. Scot Analysis
8.2.12.4. Strategic Initiatives
8.2.13. Shire
8.2.13.1. Overview
8.2.13.2. Product Portfolio
8.2.13.3. Scot Analysis
8.2.13.4. Strategic Initiatives
8.2.14. Sun Pharmaceutical Industries Ltd
8.2.14.1. Overview
8.2.14.2. Products Portfolio
8.2.14.3. Scot Analysis
8.2.14.4. Strategic Initiatives
8.2.15. Ultragenyx Pharmaceutical Inc.
8.2.15.1. Overview
8.2.15.2. Product Portfolio
8.2.15.3. Scot Analysis
8.2.15.4. Strategic Initiatives
8.2.16. Zeria Pharmaceutical
8.2.16.1. Overview
8.2.16.2. Product Portfolio
8.2.16.3. Scot Analysis
8.2.16.4. Strategic Initiatives
List Of Tables
Table 1 Asia Pacific Hyperphosphatemia Drug Market 2019-2027($ Million)
Table 2 Iron-based Hyperphosphatemia Drug Approval Status 2014-2017
Table 3 Worldwide Population Aged 80 And Above 1950-2050 (Millions)
Table 4 Phosphorous Levels In Select Foods
Table 5 Asia Pacific Hyperphosphatemia Drugs Market By Formulation 2019-2027($ Million)
Table 6 Asia Pacific Calcium-based Phosphate Binders 2019-2027($ Million)
Table 7 Asia Pacific Aluminum-based Phosphate Binders 2019-2027($ Million)
Table 8 Asia Pacific Magnesium-based Phosphate Binders 2019-2027($ Million)
Table 9 Asia Pacific Iron-based Phosphate Binders 2019-2027($ Million)
Table 10 Asia Pacific Other Phosphate Binders 2019-2027($ Million)
Table 11 Pipeline Portfolio Of Hyperphosphatemia Drugs
Table 12 Asia Pacific Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Table 13 Asia-pacific Hyperphosphatemia Drugs Market By Country 2019-2027($ Million)
Table 14 Per Capita Consumption Of Dairy Products In Australia 2014 -2016
List Of Figures
Figure 1 Rate Of Adherence To Phosphate Binders
Figure 2 Diagnosis And Clinical Indicators Of Chronic Kidney Disease
Figure 3 Asia Pacific Hyperphosphatemia Drugs Market By Calcium-based Phosphate Binders 2019-2027($ Million)
Figure 4 Asia Pacific Hyperphosphatemia Drugs Market By Aluminum-based Phosphate Binders 2019-2027($ Million)
Figure 5 Asia Pacific Hyperphosphatemia Drugs Market By Magnesium-based Phosphate Binders 2019-2027($ Million)
Figure 6 Asia Pacific Hyperphosphatemia Drugs Market By Iron-based Phosphate Binders 2019-2027($ Million)
Figure 7 Asia Pacific Hyperphosphatemia Drugs Market By Other Phosphate Binders 2019-2027($ Million)
Figure 8 Porters 5 Force Model Of Hyperphosphatemia Market
Figure 9 Asia-pacific Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 10 Age Wise Distribution Of Elderly Population In India 2016
Figure 11 India Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 12 China Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 13 Japan Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 14 Number Of Fractures Due To Osteoporosis And Osteopenia ($ Million)
Figure 15 Australia Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 16 South Korea Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 17 Roapac Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 18 Market Share Analysis Of Key Players 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report